Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

DAPT clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our China, Italy, Japan and South Korea registers that name DAPT as an intervention. Synced 9 Nov 2026
7Current trials
7Recruiting now
7Lead sponsors
4Country registers
At a glance

DAPT is named as an intervention in 7 current clinical trials in our China, Italy, Japan and South Korea registers. 7 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Zunyi Medical College (1). The most-studied condition is STEMI - ST Elevation Myocardial Infarction.

Patient leaflets for DAPT

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting7100%

Trials by phase

  • Phase 4457%
  • Not applicable229%
  • Phase 2114%
01

Clinical trials of DAPT

7 trials
StudyPhaseStatusLead sponsorRegisters
Ticagrelor De-escalation Strategy in AMI Patients
NCT04755387 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction
Phase 4 Recruiting Dong-A University South Korea
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
NCT05782270 · ClinicalTrials.gov ↗ · Anticoagulation, Coronary Endarterectomy
Phase 4 Recruiting China National Center for Cardiovascular Diseases China
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
NCT06013020 · ClinicalTrials.gov ↗ · STEMI - ST Elevation Myocardial Infarction
Phase 4 Recruiting Zunyi Medical College China
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
NCT07111559 · ClinicalTrials.gov ↗ · Lacunar Stroke, Stroke, Ischemic Stroke
Phase 4 Recruiting Nippon Medical School Japan
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
NCT07000617 · ClinicalTrials.gov ↗ · NK/T Cell Lymphoma
Phase 2 Recruiting Peking University Cancer Hospital & Institute China
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
NCT06535568 · ClinicalTrials.gov ↗ · Coronary Disease, Heart Diseases, Cardiovascular Diseases
Not applicable Recruiting Fondazione Ricerca e Innovazione Cardiovascolare ETS Italy
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
NCT07587099 · ClinicalTrials.gov ↗ · Coronary Heart Disease (CHD)
Not applicable Recruiting Gan Lijun China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with DAPT

13 conditions
STEMI - ST Elevation Myocardial Infarction1NK/T Cell Lymphoma1Coronary Heart Disease (CHD)1Anticoagulation1Coronary Endarterectomy1Coronary Disease1Heart Diseases1Cardiovascular Diseases1Myocardial Ischemia1Lacunar Stroke1Stroke1Ischemic Stroke1
All 13 conditions
Condition (as registered)Trials
STEMI - ST Elevation Myocardial Infarction1
NK/T Cell Lymphoma1
Coronary Heart Disease (CHD)1
Anticoagulation1
Coronary Endarterectomy1
Coronary Disease1
Heart Diseases1
Cardiovascular Diseases1
Myocardial Ischemia1
Lacunar Stroke1
Stroke1
Ischemic Stroke1
Acute Myocardial Infarction1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Zunyi Medical College1
Peking University Cancer Hospital & Institute1
Gan Lijun1
China National Center for Cardiovascular Diseases1
Fondazione Ricerca e Innovazione Cardiovascolare ETS1
Nippon Medical School1
Dong-A University1
04

By country register

RegisterTrialsRecruiting
Clinical trials in China44
Clinical trials in Italy11
Clinical trials in Japan11
Clinical trials in South Korea11

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about DAPT trials

How many clinical trials are testing DAPT?

7 current trials in our China, Italy, Japan and South Korea registers name DAPT as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are DAPT trials recruiting patients?

Yes. 7 of the 7 trials are recruiting: 4 with sites in China, 1 with sites in Italy, 1 with sites in Japan and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors DAPT clinical trials?

Zunyi Medical College (1), Peking University Cancer Hospital & Institute (1), Gan Lijun (1) and China National Center for Cardiovascular Diseases (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how DAPT works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how DAPT works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists DAPT (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.